IMAVVY approved as first targeted therapy for wAIHA

IMAVVY has been FDA-approved as the first targeted therapy for warm autoimmune haemolytic anaemia (wAIHA), selectively reducing pathogenic IgG autoantibodies while preserving B-cell function, based on pivotal phase 2/3 trial data demonstrating durable haemoglobin response and fatigue improvement.

This Wire brief sits within Fusion42's coverage of Biotech.